OMRIX Biopharmaceuticals, Inc. (“OMRIX”
or the “Company”)
(NASDAQ: OMRI), a fully-integrated biopharmaceutical company that
develops and markets biosurgical and immunotherapy products, announced
today that it has rescheduled the announcement of its financial results
and accompanying conference call for the third quarter ended September
30, 2008 to an earlier time. The Company will now announce its financial
results before the opening of the U.S. financial markets on Thursday,
November 6, 2008 and the accompanying conference call to discuss the
results will be held at 8:00 am ET; 5:00 am PT.
To access the live telephonic broadcast, U.S. callers should dial (866)
825-1709; international callers may dial (617) 213-8060 and provide
confirmation code 60018854. A live audio webcast of the call will be
available via the Investor Relations' section of the Company's website
at www.omrix.com.
Participants are urged to log on to the website 15 minutes prior to the
scheduled start time to download and install any necessary software.
An audio replay of the conference call will be available from 10:00 am
ET on Thursday, November 6, 2008 through Thursday, November 13, 2008 by
dialing (888) 286-8010 from the U.S. or (617) 801-6888 when calling
internationally, and entering confirmation code 83921144. The audio
webcast will be available on the company's website, www.omrix.com,
for 30 days. The financial results press release will also be accessible
on the company's website at www.omrix.com.
About Omrix Biopharmaceuticals, Inc.
Omrix is a fully integrated biopharmaceutical company that develops,
manufactures and markets protein-based biosurgery and passive
immunotherapy products. Omrix' biosurgery product line includes products
and product candidates that are used for the control of bleeding, or
hemostasis, and other surgical applications. The Company's passive
immunotherapy product line includes antibody-rich products and product
candidates for the treatment of immune deficiencies, infectious diseases
and potential biodefense applications. For more information, please
visit www.omrix.com.
Safe Harbor Statement
This news release contains forward-looking statements. Forward-looking
statements provide the Company's current expectations or forecasts of
future events. Forward-looking statements include statements about the
Company's expectations, beliefs, plans, objectives, intentions,
assumptions and other statements that are not historical facts.
Forward-looking statements are subject to known and unknown risks and
uncertainties and are based on potentially inaccurate assumptions that
could cause actual results to differ materially from those expected or
implied by the forward-looking statements. The Company's actual results
could differ materially from those anticipated in forward-looking
statements for many reasons, including the factors described in the
Company's filings with the Securities and Exchange Commission (SEC),
including sections entitled "Risk Factors" and "Management's Discussion
and Analysis of Financial Condition and Results of Operations" in the
Company's Form 10-K as filed with the SEC on March 17, 2008, and the
Company's most recent quarterly reports on Form 10-Q and its current
reports on Form 8-K. Unless required by law, the Company undertakes no
obligation to publicly update or revise any forward-looking statement to
reflect circumstances or events after the date of this news release.
Omrix Biopharmaceuticals, Inc.
Francesca M. DeMartino, 212-887-6510
Senior
Director, Investor Relations
francesca.demartino@omrix.com
